The discovery and development of omalizumab for the treatment of asthma

Bibliography

• Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97:75-85
   PubMed Web of Science ®Google Scholar
• Stanworth DR. The discovery of IgE. Allergy 1993;48:67-71
   PubMed Web of Science ®Google Scholar
• Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ J 2014;7:17
   PubMedGoogle Scholar
• Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001;108:S65-71
   PubMed Web of Science ®Google Scholar
• From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2014. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf
   Google Scholar
• Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252-62
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73
   PubMed Web of Science ®Google Scholar
• Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157-62
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-65
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;1:CD003559
   PubMed Web of Science ®Google Scholar
• Hook WA, Berenstein E, Basciano LA, et al. Monoclonal antibodies to human IgE. Fed Proc 1981;40:968(A4177)
   Google Scholar
• Baniyash M, Eshhar Z. Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. Eur J Immunol 1984;14:799-807
   PubMed Web of Science ®Google Scholar
• Baniyash M, Kehry M, Eshhar Z. Anti-lgE monoclonal antibodies directed at the Fc receptor binding site. Mol Immuno1 1988;25:705-11
   PubMed Web of Science ®Google Scholar
• Heusser CH, Bews J, Brinkmann V, et al. New concepts of IgE regulation. Int Arch Allergy Appl Immunol 1991;94:87-90
   PubMedGoogle Scholar
• Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997;9:805-13
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson M J, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851-5
   PubMed Web of Science ®Google Scholar
• Reichmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7
   PubMed Web of Science ®Google Scholar
• Logsdon SL, Oettgen HC. Anti-IgE Therapy: Clinical Utility and Mechanistic Insights. Curr Top Microbiol Immunol 2015;388:39-61
   PubMed Web of Science ®Google Scholar
• Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:2623-32
   PubMed Web of Science ®Google Scholar
• Haak-Frendscho M, Robbins K, et al. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 1994;82:306-13
   PubMed Web of Science ®Google Scholar
• Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997;99:879-87
   PubMed Web of Science ®Google Scholar
• Holgate ST, Djukanović R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005;35:408-16
   PubMed Web of Science ®Google Scholar
• MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 2004;114:1472-4
   PubMed Web of Science ®Google Scholar
• Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004;114:527-30
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-54
   PubMed Web of Science ®Google Scholar
• Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010;125:896-901.e6
   PubMed Web of Science ®Google Scholar
• Pelaia G, Gallelli L, Renda T, et al. Update on optimal use of omalizumab in management of asthma. J Asthma Allergy 2011;4:49-59
   PubMedGoogle Scholar
• Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5211lbl.pdf
   Google Scholar
• Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34:10474-82
   PubMed Web of Science ®Google Scholar
• Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996;279:1000-8
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34
   PubMed Web of Science ®Google Scholar
• Boulet LP, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-40
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RBJr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341:1966-73
   PubMed Web of Science ®Google Scholar
• Casale T, Racine A, Sallas W, et al. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:S357
   Web of Science ®Google Scholar
• Aderoth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36
   PubMed Web of Science ®Google Scholar
• Lemanske RFJr, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002;110(5):e55
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs 2014;16:491-502
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210-16
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 2011;27:163-9
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-15
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009;103:1633-42
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012;6:215-27
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the ’real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 2013;107:1141-51
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013;42:1224-33
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011;139:28-35
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97
   PubMed Web of Science ®Google Scholar
• Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012;129:983-9.e6
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014;134:560-567.e4
   PubMed Web of Science ®Google Scholar
• Li J, Goulding M, Seymour S, Starke P. EXCELS study results do not rule out potential cancer risk with omalizumab. J Allergy Clin Immunol 2015;135:289
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication. FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm414911.htm
   Google Scholar
• Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265-9
   PubMed Web of Science ®Google Scholar
• Domínguez-Ortega J, Phillips-Anglés E, Barranco P, Quirce S. Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma 2015;1
   PubMedGoogle Scholar
• Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011;180:637-41
   PubMed Web of Science ®Google Scholar
• Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis 2012;6:87-95
   PubMed Web of Science ®Google Scholar
• van Nooten F, Stern S, Braunstahl GJ, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013;16:342-8
   PubMedGoogle Scholar
• Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013;17:1-342
   PubMed Web of Science ®Google Scholar
• McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs 2013;73:1197-212
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol 2011;72:306-20
   PubMed Web of Science ®Google Scholar
• Nopp A, Johansson SG, Adédoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010;65:56-60
   PubMed Web of Science ®Google Scholar
• Roth M, Zhong J, Zumkeller C, et al. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLoS One 2013;8:e56015
   PubMed Web of Science ®Google Scholar
• Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol 2012;25:475-84
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101:1483-92
   PubMed Web of Science ®Google Scholar
• Busse W, Spector S, Rosén K, et al. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 2013;132:485-6.e11
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-11
   PubMed Web of Science ®Google Scholar
• Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett 2014;162:2-10
   PubMed Web of Science ®Google Scholar